0.8226
price down icon3.22%   -0.0274
 
loading
전일 마감가:
$0.85
열려 있는:
$0.8245
하루 거래량:
122.40K
Relative Volume:
0.27
시가총액:
$7.09M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+11.31%
1개월 성능:
-48.07%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
Value
$0.8007
$0.85
1주일 범위
Value
$0.67
$0.86
52주 변동 폭
Value
$0.647
$2.75

Metavia Inc Stock (MTVA) Company Profile

Name
명칭
Metavia Inc
Name
전화
(857) 702-9600
Name
주소
545 CONCORD AVENUE, CAMBRIDGE
Name
직원
8
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
MTVA's Discussions on Twitter

MTVA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
MTVA
Metavia Inc
0.8226 7.09M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Metavia Inc Stock (MTVA) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-12-30 개시 H.C. Wainwright Buy

Metavia Inc 주식(MTVA)의 최신 뉴스

pulisher
Apr 24, 2025

MetaVia’s Promising Clinical Trial Results and Future Prospects Drive Buy Rating - TipRanks

Apr 24, 2025
pulisher
Apr 23, 2025

MetaVia’s DA-1241 shows promise in Phase 2a MASH trial By Investing.com - Investing.com South Africa

Apr 23, 2025
pulisher
Apr 23, 2025

Copper Miner Rallies as Takeover Buzz Sparks Investor Optimism - The Globe and Mail

Apr 23, 2025
pulisher
Apr 23, 2025

MetaVia’s DA-1241 shows promise in Phase 2a MASH trial - Investing.com

Apr 23, 2025
pulisher
Apr 23, 2025

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 - PR Newswire

Apr 23, 2025
pulisher
Apr 22, 2025

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors - insights.citeline.com

Apr 22, 2025
pulisher
Apr 22, 2025

MetaVia reports promising obesity drug trial results By Investing.com - Investing.com South Africa

Apr 22, 2025
pulisher
Apr 22, 2025

How will MetaVia Inc’s (MTVA) earnings compare to estimates this quarter? - uspostnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

RIVN’s Q2 earnings predictions: What the experts say - uspostnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

Can Newell Brands Inc (NWL) meet market expectations this quarter? - uspostnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

MetaVia Reports Positive Phase 1 Trial Results - TipRanks

Apr 22, 2025
pulisher
Apr 22, 2025

MetaVia (MTVA) Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726 - StreetInsider

Apr 22, 2025
pulisher
Apr 22, 2025

MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential - marketscreener.com

Apr 22, 2025
pulisher
Apr 22, 2025

MetaVia's New GLP-1 Drug Achieves 6.3% Weight Loss in Just 26 Days: Phase 1 Trial Reveals Promising Safety Profile - Stock Titan

Apr 22, 2025
pulisher
Apr 21, 2025

Stock Market Recap: MetaVia Inc (MTVA) Concludes at 0.74, a 0.64 Surge/Decline - DWinneX

Apr 21, 2025
pulisher
Apr 19, 2025

MetaVia’s (MTVA) Buy Rating Reiterated at HC Wainwright - Defense World

Apr 19, 2025
pulisher
Apr 18, 2025

MTVA stock touches 52-week low at $0.7 amid sharp annual decline - Investing.com Canada

Apr 18, 2025
pulisher
Apr 17, 2025

MTVA stock touches 52-week low at $0.7 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 17, 2025
pulisher
Apr 16, 2025

MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%… - Zacks Small Cap Research

Apr 16, 2025
pulisher
Apr 16, 2025

Korean Dental Association forms election planning team to enhance public oral healthCHOSUNBIZ - Chosunbiz

Apr 16, 2025
pulisher
Apr 16, 2025

MetaVia’s obesity drug cuts body weight by 6.3% in 26 days in phase 1 - koreabiomed.com

Apr 16, 2025
pulisher
Apr 16, 2025

MetaVia reports positive obesity drug trial results By Investing.com - Investing.com Canada

Apr 16, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.39% - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

United States shares lower at close of trade; Dow Jones Industrial Average down 0.39% - Investing.com India

Apr 15, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

MetaVia Reports 'Positive' Results for Obesity Treatment in Part 2 of Phase 1 Trial - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer’s bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M - Endpoints News

Apr 15, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Smart Shirt Might Predict Heart Problems - WFMZ.com

Apr 15, 2025
pulisher
Apr 15, 2025

MetaVia reports positive obesity drug trial results - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

MetaVia Announces Positive Phase 1 Trial Results - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

Metavia Announces Positive Top-Line Data From The 4-Week Phase 1 Mad Trial Of Da-1726 - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

MetaVia announces ‘positive’ results from Part 2 of Phase 1 trial of DA-1726 - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

MetaVia (MTVA) Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726 - StreetInsider

Apr 15, 2025
pulisher
Apr 15, 2025

MetaVia's New GLP-1 Drug Achieves 6.3% Weight Loss Without TitrationGame-Changing Trial Results - Stock Titan

Apr 15, 2025
pulisher
Apr 14, 2025

Home-Delivered Medical Meals Could Prevent Millions Of Hospitalizations A Year - WFMZ.com

Apr 14, 2025
pulisher
Apr 14, 2025

SCHD ETF News, 4/14/2025 - The Globe and Mail

Apr 14, 2025
pulisher
Mar 31, 2025

MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon… - Yahoo Finance

Mar 31, 2025
pulisher
Mar 24, 2025

MetaVia Inc. Reports Progress in Cardiometabolic Drug Development - MSN

Mar 24, 2025
pulisher
Mar 24, 2025

Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy - TradingView

Mar 24, 2025
pulisher
Mar 24, 2025

FY2029 Earnings Forecast for MetaVia Issued By HC Wainwright - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

HC Wainwright Reaffirms “Buy” Rating for MetaVia (NASDAQ:MTVA) - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

Positive Outlook on MetaVia’s Promising Pipeline and Strategic Growth Despite Market Challenges - TipRanks

Mar 22, 2025
pulisher
Mar 22, 2025

MetaVia Inc (MTVA) Reports Q4 EPS of -0.59, Revenue at $0 Millio - GuruFocus

Mar 22, 2025
pulisher
Mar 20, 2025

MetaVia Inc. (MTVA) reports earnings - Quartz

Mar 20, 2025
pulisher
Mar 20, 2025

Bank of England leaves benchmark interest rate unchanged at 4.50% with inflation still high - 69News WFMZ-TV

Mar 20, 2025
pulisher
Mar 20, 2025

Stock market today: Wall Street gives back some gains after the Fed extends interest rate pause - WFMZ.com

Mar 20, 2025
pulisher
Mar 20, 2025

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update - PR Newswire

Mar 20, 2025
pulisher
Mar 20, 2025

Tonsil Removal Helps Kids With Snoring/Sleep Apnea - 69News WFMZ-TV

Mar 20, 2025
pulisher
Mar 20, 2025

New Clot-Busting Drug Quicker And As Effective In Treating Stroke - 69News WFMZ-TV

Mar 20, 2025

Metavia Inc (MTVA) 재무 분석

Metavia Inc (MTVA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
자본화:     |  볼륨(24시간):